Literature DB >> 8938099

Upregulation of adhesion molecule expression on endothelial cells by anti-DNA autoantibodies in systemic lupus erythematosus.

K N Lai1, J C Leung, K B Lai, K C Wong, C K Lai.   

Abstract

The mechanism of vasculopathy in systemic lupus erythematosus (SLE) remains unclear and the evidence for a direct pathogenic role of anti-double-stranded DNA antibodies (anti-dsDNA) is not strong. Our study aims to determine whether anti-dsDNA exerts any effect on the expression of adhesion molecules on endothelial cells. IgG was purified from 17 patients with SLE (median anti-dsDNA titer, 404 IU/ml) and from 9 healthy controls (median titer 16 IU/ml). Anti-dsDNA-depleted polyclonal IgG (anti-dsDNA-dep-IgG) (median anti-dsDNA titer 17 IU/ml) was prepared from sera of these patients with SLE by affinity chromatography with DNA cellulose column. Expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin on human umbilical vein endothelial cells (HUVEC) cultured with either control IgG or anti-dsDNA were compared by flow cytometry. The levels of adhesion molecules in the supernatant of cultured HUVEC were assessed by sandwich ELISA. Compared with either control IgG or anti-dsDNA-dep-IgG, HUVEC incubated with anti-dsDNA expressed a significantly higher mean fluorescence intensity of ICAM-1 and in VCAM-1 and a higher supernatant concentration of ICAM-1 and VCAM-1 but not E-selectin. At the same time, ICAM-1 mRNA was also raised with increased neutrophil adherence in HUVEC incubated with anti-dsDNA. Pretreatment of HUVEC with native DNA or histone before incubation with anti-dsDNA did not increase the expression of adhesion molecules. Our study provides in vitro evidence that anti-dsDNA could play an important pathogenic role in inducing inflammatory injury of vascular endothelium in SLE.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938099     DOI: 10.1006/clin.1996.0183

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  6 in total

1.  Dendritic cells from lupus-prone mice are defective in repressing immunoglobulin secretion.

Authors:  Mileka R Gilbert; Diane G Carnathan; Patricia C Cogswell; Li Lin; Albert S Baldwin; Barbara J Vilen
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

2.  Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein.

Authors:  M Okawa-Takatsuji; S Aotsuka; M Fujinami; S Uwatoko; M Kinoshita; M Sumiya
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 3.  Rationale for interleukin-6 blockade in systemic lupus erythematosus.

Authors:  E Tackey; P E Lipsky; G G Illei
Journal:  Lupus       Date:  2004       Impact factor: 2.911

4.  Relationship between antinuclear antibody and microalbuminuria in the general population: the Takahata study.

Authors:  Mizue Ishikawa; Tsuneo Konta; Zhimei Hao; Satoshi Takasaki; Hiroshi Abiko; Toshiyuki Takahashi; Ami Ikeda; Kazunobu Ichikawa; Yoko Shibata; Yasuchika Takeishi; Takeo Kato; Sumio Kawata; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2008-02-13       Impact factor: 2.801

5.  The Usefulness of Endothelial Cell Adhesion Molecules and Anti-C1q Antibody in Monitoring Systemic Lupus Erythematosus Disease Activity.

Authors:  Hasni Mahayidin; Nurul Khaiza Yahya; Wan Syamimee Wan Ghazali; Asmahan Mohd Ismail; Wan Zuraida Wan Ab Hamid
Journal:  Int Sch Res Notices       Date:  2014-10-29

6.  'Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patients'.

Authors:  C Pérez-Sánchez; M A Aguirre; P Ruiz-Limón; N Barbarroja; Y Jiménez-Gómez; I Arias de la Rosa; A Rodriguez-Ariza; E Collantes-Estévez; P Segui; F Velasco; M J Cuadrado; R Teruel; R González-Conejero; C Martínez; Ch López-Pedrera
Journal:  Sci Rep       Date:  2016-08-09       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.